<DOC>
	<DOCNO>NCT02793557</DOCNO>
	<brief_summary>A study investigate clinical safety effect hair growth FOL-005 healthy volunteer . The study divide two part , single ascend dose ( SAD ) part multiple dose ( MD ) part .</brief_summary>
	<brief_title>Investigation FOL-005 Clinical Safety Effect Hair Growth</brief_title>
	<detailed_description>SAD part : A total 3 week dose , two low concentration week 1 , dose 3 week 2 finally dose 4 week 3 . MD part : In total 12 week dose group A dose twice weekly group B three time weekly Each injection administer one five six randomize area ( 10 cm apart , leave right side ) subject 's defined investigational skin area . One area completely untreated .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Hirsutism</mesh_term>
	<mesh_term>Hypertrichosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male , age 1845 year Clinically visible terminal hair growth thigh Damaged skin around test site History acute ( e.g . acute infection ) chronic illness know skin cancer might confound result trial History clinical sign keloid hypertrophic scar Immunological disorder alopecia areata , systemic lupus erythematosus Current within 2 week prior first dose use vasodilating drug ( e.g . Pentoxifyllin , nitroglycerine ) anticoagulating drug ( e.g . heparine , cumarines , new oral anticoagulant ) Current within 3 month prior first dose use antiinflammatory medication , corticosteroid immunosuppressive drug take 2 consecutive week Current within 3 month prior first dose use medication hair growth modify property like minoxidil , diazoxid , cyclosporine , antiandrogens Current within 12 month prior first dose intake anabolics 5alpha reductase inhibitor Current within one week prior first dose use topical drug leg</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>